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Abstract   
 
The new type of Coronavirus (SARS-CoV-2) is a highly contagious pathogen that causes severe acute respiratory 
syndrome and can be transmitted from human to human. COVID-19, which has been declared as a pandemic by the 
world health organization and is infected with more than 50 million people, is also responsible for the death of more 
than 1 million people. There is no sufficient data from randomized clinical trials that any potential treatment improves 
outcomes in COVID-19 patients. Chloroquine and hydroxychloroquine, antivirals such as favipiravir, lopinavir/ritonavir, 
immunomodulatory agents tocilizumab, siltuximab, and sarilumab, and anti-inflammatory drugs such as steroids are 
used for the treatment of COVID-19. Repurposing drugs can provide new treatment options faster than discovering 
new drugs due to the known safety profiles of existing drugs. On the other hand, there are new drug and vaccine trials 
for COVID-19. Many researchers, governmental or non-governmental institutions having clinical trials for COVID-19 
drugs and vaccines. In this comprehensive review, we investigate the clinical features, management, and treatment of 
COVID-19 and possible adverse effects and important information related to drugs used for COVID-19. For future 
preparedness and readiness, new laws and legislations should be constituted. Besides, emergency teams and 
budgets should be prepared as well.  
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Background  
In December 2019, a novel coronavirus that caused a severe 
coronavirus disease emerged first in Wuhan, China [1]. It 
probably originated from bat-derived coronaviruses that spread 
to humans through an unknown intermediate mammal host [2]. 
This virus has been identified as a new enveloped RNA 
betacoronavirus [1]. The novel betacoronavirus is similar to 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 
and Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV). Considering phylogenetic similarity with SARS-CoV, it 
has been named Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2), and in the months that followed, 
it has spread worldwide, causing the current pandemic [2,3]. 
WHO announced on January 30 that the SARS-CoV-2 
epidemic was a Public Health Emergency of International 
Concern (PHEIC) [1].  
     Viruses have four major structural proteins: spike (S), 
envelope (E), nucleocapsid (N), membrane (M) [4]. S 
glycoprotein is on its surface, and SARS-CoV-2 mainly infects 
ciliated bronchial epithelial cells and type II pneumocytes 
through the S glycoprotein that binds to the angiotensin-
converting enzyme 2 (ACE2) surface receptor. When S 
glycoprotein binds to ACE2, the cell surface-associated 
transmembrane serine two proteases (TMPRSS2) and cathepsin 
trigger trimer S protein cleavage. S glycoprotein contains S1 
and S2 subunits. While S1 determines host diversity and 
facilitates viral binding to target cells, S2 mediates the fusion of 
viral and cellular membranes and provides a viral entry with 
endocytosis [5]. As soon as the virus enters the cell, viral 
polyproteins encoding the replicase-transcriptase complex are 
synthesized. The virus then synthesizes RNA with RNA-
dependent RNA polymerase. Structural proteins are synthesized 
and lead to the release of viral particles. Non-structural proteins 
that share homology with other novel coronaviruses (nCoVs) 
(e.g., 3-chymotrypsin-like protease, RNA-dependent RNA 
polymerase) are promising drug targets. Viral entry and 
immune regulation pathways are also among the additional drug 
targets [2]. In this study, we try to summarize the clinical 
features of COVID-19 and possible ups and downs of the 
treatment options for COVID-19. There is a vast amount of 
drug and vaccination clinical trials to treat COVID-19. 
 
Methods  
Study design  
This study has been structured as a comprehensive review. 
Treatment guidelines, clinical studies, systematic reviews, and 
case studies were included in our study. The current English 
and Turkish literature published in PubMed, Medline, Web of 
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Science, EMBASE, Türkiye Atif Dizini search engines 
reviewed.  
To minimize bias, information collected from each study 
included: (1) design and characteristics of study; (2) clinical 
feature and possible effects on COVID-19; (3) the type of 
outcome measure. 
 
Clinical findings, symptoms, and diagnosis of COVID-19  
COVID-19 symptoms are generally nonspecific. While most 
common symptoms are fever and cough, common symptoms 
are fatigue, myalgia, dyspnea, altered sense of smell/taste, 
anorexia, sputum production/expectoration, sore throat [1,6,7]. 
Gastrointestinal symptoms, confusion, dizziness, headache, 
rhinorrhoea or nasal congestion, haemoptysis, chest pain, 
conjunctivitis, cutaneous manifestations (e.g. Maculopapular 
rash), bronchial breath sounds, tachypnoea, tachycardia, 
cyanosis, crackles/rales on auscultation are rare [7]. 
     The incubation period in COVID-19 is within 14 days after 
exposure. The average incubation period is four days 
(interquartile range, 2–7 days) [8]. The positive result of a high-
throughput sequencing, positive result of an RT-PCR assay for 
respiratory samples (e.g., nasopharyngeal swab), or a positive 
result of anti-SARS-CoV-2 IgM/IgG may help to confirm the 
diagnosis of COVID-19 [9]. RT-PCR may tend to present the 
negative result at an average of 5.1 days. It is recommended to 
repeat the test 3 days after a negative result [10]. Gene 
sequencing is pricey and very time-consuming. Serological tests 
can be used for rapid screening in the clinics because they can 
have resulted in 15 minutes [1]. Laboratory values that suggest 
COVID-19 disease include lymphopenia, prolonged 
prothrombin time (PT), eosinopenia, increased lactate 
dehydrogenase (LDH), increased alanine aminotransferase 
(ALT), increased aspartate aminotransferase (AST), increased 
D-dimer, increased neutrophils, increased C-reactive protein 
(CRP) and increased troponin [10]. Radiological findings have 
been shown to vary depending on the initial medical 
intervention, patient's age, disease progression, immune status, 
and comorbidity [6]. When chest computed tomography (CT) 
for patients with novel coronavirus pneumonia is used, typical 
imaging features such as patchy bilateral shadows, 
subsegmental areas of ground-glass opacity, or consolidation 
are observed. Changes in imaging reflect the severity of the 
disease [11]. It may be recommended for suspected COVID-19 
patients or those with a negative RT-PCR test. Abnormal chest-
CT may do not mean that a patient does not have COVID-19. 
However, regular chest CT is not specific to determine the 
diagnosis of COVID-19. A chest X-ray is required for patients 
with suspected pneumonia and shows unilateral-bilateral lung 
infiltrates [7]. Currently, the diagnosis of COVID-19 is 
especially based on epidemiological history, clinical features, 
laboratory detection, and chest imaging [9]. 
     According to published guidelines in China, disease severity 
was classified into mild, moderate, severe, and critical: - 
 1) Mild type: Asymptomatic or some upper respiratory tract 
infection symptoms are mild, no pneumonia manifestations.  
2) Moderate type: Similar clinical symptoms and pneumonia 
manifestations can be seen in imaging [12].  
3) Severe type: Disease progression with danger signs; when 
any of these criteria exist: respiratory rate ≥ 30 breaths/min; 
oxygen saturation ≤ 93% at a rest state; arterial partial pressure 
of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg. 
Patients with > 50% lesions progression within 24 to 48 hours 
in lung [13].  
4) Critical type: Shock or organ failure that requires intensive 
care [12]. 
 
Prevention and control  
Currently, there is no vaccine or approved specific therapy for 
COVID-19; thus, prevention is vital to control it. People can 
reduce their chances of being infected with several basic 
methods. However, some factors make the prevention process 
more difficult. People with the infection do not necessarily 
show the symptoms, but they still can spread the virus. SARS-
CoV-2 has a long incubation period. In some situations, 
transmission can occur even after clinical recovery. These are 
some of the factors that make prevention difficult [14]. 
     People should take precautions to avoid being exposed to the 
virus [15]. There are several recommendations about 
prevention, but the most important one is careful about personal 
hygiene. Hands should be washed with soap and water for at 
least 20 seconds; alcohol-based hand sanitizers, which contain 
at least %60 alcohol, also can be used. It is recommended to 
avoid touching eyes, nose, and mouth. Moreover, people should 
maintain at least 1 meter distance from others, especially 
individuals with symptoms [16]. It is also recommended to 
avoid going to crowded places because, in these places, people 
are more likely to come into close contact with each other, so 
maintaining physical distance is more difficult [17]. People 
should cover their nose and mouth with a tissue or inner side of 
their elbow when they cough or sneeze [18]. These are simple 
but crucial recommendations in order to reduce the transmission 
of the infection.  
     People should stay at home and isolate themselves from 
other people, even with minor symptoms such as cough, 
headache, and mild fever. If patients have more severe 
symptoms such as difficulty breathing and fever, they should 
follow health authorities' directions. People with either mild or 
severe symptoms should wear a medical mask to leave their 
houses [17]. Patients with chronic comorbidities or older than 
65 age are in the high-risk group. Thus, even though they do not 
have any symptoms, they stay at home as far as possible to 
reduce the risk of being infected [16]. 
     Health care workers are also at high-risk because they 
frequently contact infected patients. It is crucial to protect 
health care workers; otherwise, patients cannot be treated, and 
transmission of infection to other patients become easier [14]. 
Therefore, health care workers who contact COVID-19 patients 
require full personal protective equipment. Prior to performing 
procedures that generate aerosol, health care workers are 
recommended to use N95 and FFP2 masks [15,16]. 
 
Potential therapeutic agents for COVID-19 treatment  
There is no sufficient data from randomized clinical trials that 
any potential treatment improves outcomes in COVID-19 
patients. Moreover, no prophylactic treatment has been 
recommended [2]. The current treatment consists of antiviral, 
supportive, and symptomatic treatment, which are decided to 
depend on the patient's clinical condition. Supportive treatments 
are fever and pain management, oxygen treatment, fluid intake, 
and antibiotic treatment in the presence of an additional 
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bacterial infection [19]. Table 1 and Table 2 summarizes the 
properties of potential therapeutic agents for the treatment of 
COVID-19. 
 
Chloroquine and hydroxychloroquine 
Chloroquine (CQ) has been described as a possible broad-
spectrum antiviral drug, and it is used for the prevention and 
treatment of malaria treatment of chronic inflammatory diseases 
such as systemic lupus erythematosus (SLE) and rheumatoid 
arthritis [2,20]. It has an antiviral effect against various RNA 
viruses such as rabies virus, hepatitis virus, and HIV [20]. 
Chloroquine and its hydroxy derivative, hydroxychloroquine 
(HCQ), act by preventing glycosylation at the host receptor, 
increasing the endosomal pH, and inhibiting the proteolytic 
process, so they block viral entry into the cells [2]. Chloroquine 
has an in vitro effect against SARS-CoV-1 and MERS-CoV 
[21]. There is no high-quality evidence for the therapeutic 
efficacy of chloroquine/ hydroxychloroquine in SARS or 
MERS [2]. In vitro, chloroquine and hydroxychloroquine 
activity have been reported in infected Vero E6 cells against 
SARS-CoV-2 [21]. Numerous clinical trials are examining the 
efficacy and safety of chloroquine and hydroxychloroquine. 
Several researchers have proposed chloroquine and 
hydroxychloroquine in the treatment of COVID-19 because of 
the similarities to SARS-CoV infection [22]. However, these 
agents' efficacy and safety for treatment and prevention are not 
established [21][23]. Now, there are more than 80 trials 
worldwide investigating the use of chloroquine, 
hydroxychloroquine as monotherapy, or in combination with 
other agents [24]. Due to their mechanisms of preventing viral 
entry and evidence of efficacy, chloroquine and 
hydroxychloroquine have also been suggested as potential 
therapeutic agents for prophylaxis against the COVID-19. 
However, there are limited data available about this situation, so 
usage of CQ and HCQ as prophylactic agents is not 
recommended except in the context of a clinical trial [25].  
     Chloroquine and hydroxychloroquine are well tolerated in 
patients with malaria and SLE [2]. Even though they have 
similar activity, hydroxychloroquine has fewer toxicities and 
drug-drug interactions than chloroquine due to the hydroxyl 
group in its structure [26]. Nevertheless, both agents can cause 
serious adverse effects [2]. They cause cardiac adverse effects 
such as QTc prolongation, Torsade de Pointes, ventricular 
arrhythmia, and cardiac deaths. The incidence of QTc 
prolongation is greater for chloroquine than 
hydroxychloroquine. Concomitant use of medications that cause 
QTc prolongation such as antiarrhythmics, antipsychotics, 
antifungals, macrolides, and fluoroquinolones should be 
avoided and preferred only if necessary. Baseline and follow-up 
ECG are recommended when there are potential drug 
interactions with concomitant medications (e.g., azithromycin) 
or underlying cardiac diseases [2,27].  
     In patients with a clinical condition that also causes QTc 
prolongation, azithromycin should not be used in treatment 
[28]. The other adverse effects include hypoglycemia, rash, 
nausea, retinopathy, and bone marrow suppression. The 
incidence of nausea may be reduced with divided daily doses. 
Retinopathy and bone marrow suppression generally occur in 
the long-term use of CQ and HCQ [27]. 
The hemodynamic complications usually occur with 
excessively high doses. However, QTc prolongation may occur 
with the standard doses even there are no concomitant 
electrolyte abnormalities such as hypomagnesemia and 
hypokalemia [29]. Moreover, the risk of hemolysis in patients 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency is 
high with the use of CQ. There is no evidence about hemolysis 
for the use of HCQ. Thus, hydroxychloroquine is a preferred 
agent be used in patients with G6PD deficiency [27]. The use of 
these agents in a pregnant woman is generally considered safe 
[2]. 
Currently, the use of hydroxychloroquine and chloroquine in 
patients with COVID-19 is controversial. NIH COVID-19 
Treatment Guidelines Panel does not recommend chloroquine 
or hydroxychloroquine for the treatment of COVID-19 in 
hospitalized patients. The Panel also does not recommend using 
these agents in non-hospitalized patients except in a clinical 
trial [30]. Furthermore, FDA has revoked the Emergency Use 
Authorization for HCQ and CQ. One of the reasons for this 
decision is recent data from a randomized controlled trial that 
showed no evidence of benefit in mortality with 
hydroxychloroquine treatment in patients with COVID-19 [23]. 
 
Azithromycin  
Azithromycin is a macrolide antibiotic used in the treatment of 
various infections such as respiratory, skin, and soft-tissue 
infections. Currently, azithromycin is being used off-label in 
patients with COVID-19, but its efficacy and safety for this 
indication have not been proven yet [31]. According to the 
study carried out by Garret et al. [29], azithromycin was shown 
to reinforce the effects of hydroxychloroquine. In this study, 
patients with COVID-19 were divided into three groups. Six 
patients were treated with the combination of 
hydroxychloroquine and azithromycin, 14 patients have treated 
with hydroxychloroquine as monotherapy, and the third group 
was 16 control patients with COVID-19. On day 6, all of the 
patients treated with the combination therapy exhibited a 
virological cure. 
     On the other hand, the virological cure percentage exhibition 
was 57.1% in patients treated with hydroxychloroquine 
monotherapy and 12.5% in the control group. Therefore, it is 
considered that the use of hydroxychloroquine and 
azithromycin combination might be an efficient treatment for 
COVID-19 [32]. Nevertheless, additional studies are needed to 
assess the efficacy and safety of this therapy. Furthermore, there 
are concerns associated with hydroxychloroquine and 
azithromycin combination because both drugs can cause QTc 
prolongation. Thus, it is recommended to be careful and 
monitor patients treated with the hydroxychloroquine and 
azithromycin combination [21][23]. The risk of QTc 
prolongation is higher in elderly patients with cardiac 
comorbidities, patients those taking concomitant QT-interval 
prolonging drugs, and patients with electrolyte abnormalities 
[28]. 
 
Lopinavir and Ritonavir  
Lopinavir and Ritonavir are HIV protease inhibitors, and they 
suppress the cleavage of a polyprotein into multiple functional 
proteins and inhibit 3C-like protease [20,33]. They are mainly 
used in the treatment of human immunodeficiency virus-1 
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(HIV-1) [33]. The combination of lopinavir and ritonavir has in 
vitro activity against SARS-CoV-1 and MERS-CoV. Also, in 
vitro activity of this combination against SARS-CoV-2 has 
been reported in infected Vero E6 cells [21]. According to 
recent randomized controlled trials, the average time from 
symptom onset to initiation of treatment was 13 days. In the 
SARS-CoV-1 experience, treatment was effective if treatment 
started early [34,35]. Therefore, the use of lopinavir/ritonavir 
may be useful in the early stages of SARS-CoV-2 infection and 
mild disease conditions [34]. 
     Lopinavir/ritonavir combination has been of interest for the 
treatment of COVID-19 [36]. There is limited data about 
lopinavir/ritonavir for the treatment of COVID-19, and most of 
the studies about the combination are mostly case reports and 
small, retrospective, non-randomized cohort studies. Therefore, 
it is difficult to determine the effect of Lopinavir/ritonavir in 
SARS-CoV-2 infection [2]. According to available data, there is 
no advantage over standard care for SARS CoV-2 [25]. Cao B 
et al. compared lopinavir/ritonavir's efficacy with standard care 
in 199 hospitalized patients with severe COVID-19. According 
to this open-label randomize controlled trial's results, there are 
no differences between combination treatment and standard 
care. Additionally, adverse events are more common in patients 
receiving lopinavir/ritonavir, but serious adverse events are 
common in the standard care group [36]. Although additional 
randomized controlled trials (RCTs) of lopinavir/ritonavir are 
ongoing, the current data suggest a limited role for 
lopinavir/ritonavir in COVID-19 treatment [2]. 
     Lopinavir/ritonavir combination may cause adverse effects. 
Nausea, vomiting, and diarrhea are the common adverse effects 
of this agent. Hepatotoxicity is the other adverse effect of the 
combination treatment [27]. According to a recent randomized 
clinical trial, 50% of patients who receive lopinavir/ritonavir 
treatment caused adverse effects, and 14% of patients 
discontinued therapy because of the gastrointestinal adverse 
effects [2]. When this combination is used, adverse effects and 
drug interactions should be monitored [25] because 
lopinavir/ritonavir is an inhibitor of CYP3A4, so that it may 
cause important drug interactions. 
     Lopinavir/ritonavir can be used in pregnant women. 
However, this combination's oral solution contains 42% alcohol 
and 15.3% propylene glycol, so the use of this preparation is not 
recommended in pregnancy. Once-daily use of 
lopinavir/ritonavir is also not recommended in pregnancy.  
Lopinavir/ritonavir is approved for the treatment of HIV in 
infants, children, and adolescents. However, there is no data on 




Umifenovir, known as also Arbidol, is an antiviral agent that is 
approved in China and Russia for influenza treatment and 
prophylaxis. The FDA does not approve it, so it is not available 
in the US [16]. It has in vitro activity against SARS-CoV-1 and 
SARS-CoV-2 [21]. There is an increasing interest in umifenovir 
because of its action targeting the S protein/ACE2 interaction 
and inhibiting membrane fusion of the viral envelope [2]. 
Umifenovir can be found in some guidelines for the treatment 
of COVID-19. This agent's efficacy for the treatment has not 
been established yet [21][23]. There are ongoing randomized 
clinical trials to evaluate the efficacy of umifenovir for the 
treatment of COVID-19 [2]. 
 
Remdesivir   
Remdesivir, known as GS-5734, is a monophosphate prodrug 
and has a broad spectrum of antiviral effects against Ebola and 
other RNA viruses [2,5]. Remdesivir inhibits RNA-dependent 
RNA polymerase, and also its active triphosphate form can 
compete with ATP binding to the polymerase by interfering 
with viral RNA synthesis. Relatively complete data are 
available on its safety and human pharmacokinetics [33]. It has 
been shown that remdesivir has activity against SARS-CoV and 
MERS-CoV in vitro and animal models. In vitro activity of 
remdesivir against SARS-CoV-2 has been reported in infected 
Vero E6 cells [21]. Several studies recommend that a 
combination of remdesivir with specific monoclonal antibodies 
may be an ideal option for the treatment of COVID-19 [37]. It 
has been expected that the possibility of toxicity is low with the 
use of remdesivir since it is highly selective to viral 
polymerases. It has a long intracellular half-life, so once-daily 
administration of remdesivir can be possible [34]. It is the most 
promising drug currently being investigated for COVID-19 
[21]. The use of IV remdesivir provides significant 
improvement for the first COVID-19 case in the US. After that, 
a trial has been initiated to investigate the efficacy and safety of 
remdesivir in hospitalized COVID-19 patients. In a cohort study 
of hospitalized severe COVID-19 patients, an improvement was 
observed in 36 of 53 patients [25]. Moreover, reports of case 
studies suggested that the use of remdesivir may be beneficial in 
patients with severe COVID-19 [38].  
     Remdesivir can cause adverse effects such as nausea, 
vomiting, diarrhea, elevation in serum transaminase levels, and 
prothrombin time elevation. Patients with an eGFR<50 ml/min 
are not included in some clinical trials because remdesivir 
formulation contains sulfobutylether-beta-cyclodextrin sodium 
that is cleared renally. In pregnant and pediatric patients, the 
efficacy and safety of remdesivir for COVID-19 treatment have 
not been evaluated [27]. 
 
Favipiravir  
Favipiravir, also known as T705, is a guanosine analog. It 
converts into its active phosphoribosylated form in cells and 
inhibits RNA-dependent RNA polymerase. It has a broader 
antiviral spectrum because of its mechanism of action and 
inhibitory activity on a wide range of RNA viruses such as 
flavivirus, poliovirus, rhinovirus, and is a broad-spectrum drug 
[25,39]. Favipiravir is an antiviral agent that has already been 
used in the clinic to treat patients with Ebola and Lassa viruses, 
and it is used for influenza treatment in Japan [36,40]. In vitro 
studies have shown that favipiravir inhibits SARS-CoV 2 in 
Vero E6 cells [25]. Due to these reasons, favipiravir considered 
a potential candidate for the treatment of COVID-19 [41]. 
Favipiravir has in-vitro activity against SARS-CoV-2, but it has 
shown its antiviral activity with a high concentration compared 
to chloroquine or remdesivir [42].  
    There are limited clinical experience reports that support 
favipiravir for the treatment of COVID-19 [2]. Thus, additional 
reports are necessary to determine efficacy for treatment and 
identify the optimal dosage and treatment duration [21].  In a 
randomized clinical trial that was carried out by Cao B, et al. 
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[91], the efficacy and safety of favipiravir and umifenovir have 
been investigated in 240 hospitalized patients with COVID-19. 
According to the trial results, the 7-day clinical recovery rate 
was 55.86% in the umifenovir group, and the rate was 71.43% 
in the favipiravir group. The time for fever reduction and cough 
relief was significantly shorter in the favipiravir group, but no 
difference was observed in oxygen therapy or non-invasive 
mechanical ventilation rate. Furthermore, the most common 
adverse effects were abnormal liver function tests, psychiatric, 
gastrointestinal symptoms, and elevation in serum uric acid 
levels. There is a need for additional randomized clinical trials 
about the efficacy and safety of favipiravir for the treatment of 
COVID-19 [25,36].  
     High doses of favipiravir should be used with caution due to 
lack of safety data, and it is contraindicated in pregnancy. In 
addition, if favipiravir is used with paracetamol, the 
recommended maximum daily dose of paracetamol is 3 g [21]. 
 
Immunomodulatory agents  
An increase of pro-inflammatory factors in COVID-19 disease 
can cause a cytokine storm. This condition worsens the 
prognosis of COVID-19 [12]. Thus, all patients with severe 
COVID-19 should be screened for hyper inflammation because 
immunosuppressive therapy could affirmatively affect mortality 
[43]. Interleukin 6 (IL-6) measurements can help identify the 
severity of the disease [44]. Tocilizumab, siltuximab, and 
sarilumab are monoclonal antibodies, and each of them has 
different pharmacological properties. They inhibit the IL-6 
receptor and are used for the treatment of rheumatological 
conditions [12,45]. Tocilizumab has been approved by the FDA 
to treat cytokine release syndrome, which results in excessive 
cytokine production and may consequently rapid multiple organ 
damage [12,37]. Tocilizumab may be beneficial for COVID-19 
patients who can develop such an uncontrolled immune 
response [7,21].  
     There is an uncontrolled, retrospective cohort study, 
including 21 hospitalized patients with COVID-19. According 
to this study results, tocilizumab therapy provided clinical 
improvement in oxygenation, systemic inflammation, and 
respiratory function [27]. Also, there are no adverse reactions 
reported in this study [46]. However, this study has limitations 
such as small sample size and lack of a control group [27]. 
Thus, there is a need for additional studies to assess the efficacy 
of tocilizumab and other IL-6 antagonists. In accordance with 
this purpose, numerous studies of tocilizumab, sarilumab, and 
siltuximab are ongoing in different countries [45].  
     Tocilizumab should not be used in pregnancy, neutropenia, 
active tuberculosis, active hepatitis B or C, allergy, and 
hypersensitivity. Liver function tests and thrombocyte count 
should be monitored during treatment. Patients with a history of 
diverticulitis should be monitored due to gastrointestinal 
perforation risk [28]. 
 
Corticosteroids  
Corticosteroids reduce proinflammatory cytokines. They have 
anti-inflammatory and also antifibrotic properties [12,47].  The 
use of corticosteroids for the treatment of COVID-19 is 
controversial. SARS-CoV-2 infection may cause acute lung 
injury and acute respiratory distress syndrome (ARDS) due to 
increased inflammatory responses. Corticosteroids can be useful 
in these cases as anti-inflammatory agents. However, 
corticosteroids also delay viral clearance and increase the risk 
of secondary infection [16][2]. Therefore, prior to the 
corticosteroid therapy in COVID-19 patients, the risks and 
benefits should be assessed carefully [21]. In patients with 
COVID-19, recommendations about corticosteroids' use depend 
on various factors such as the severity of illness, indication, and 
underlying medical conditions. These factors vary from patient 
to patient, so each patient should be assessed individually [27]. 
WHO, CDC, NIH, and IDSA generally do not recommend the 
routine use of corticosteroids in patients with COVID-19 unless 
corticosteroids are indicated for other reasons such as 
exacerbation of asthma, COPD, or septic shock [21]. 
 
Immunoglobulin therapy  
Passive immune treatment includes whole convalescent blood, 
convalescent plasma, human immunoglobulin, and monoclonal 
or polyclonal antibodies [12]. The use of convalescent plasma 
or hyperimmune immunoglobulin is rational since antibodies 
produced by recovered patients may help immune clearance of 
infected cells and free virus [2]. Various convalescent blood 
products have been developed to treat infectious diseases. On 
the other hand, these are difficult and expensive to produce in 
emergencies [12]. Currently, plasma collected by apheresis is 
the preferred treatment [12]. The mechanism of action has 
resulted in cell cytotoxicity, phagocytosis, and direct 
neutralization of the pathogen by binding the transfused 
antibodies to the pathogen [26]. Convalescent plasma has been 
used previously for SARS-CoV-1, MERS, Ebola, and H1N1 
influenza, and successful results have been reported [34]. In a 
case study associated with COVID-19, a severely ill patient was 
treated with convalescent plasma from six donors. While anti-
SARS-CoV IgG titers from the convalescent plasma were high, 
anti-SARS-CoV IgM titers were weak [48].  
However, this approach has several disadvantages, including 
the difficulty of scaling for the widespread use and the risk of 
transmission of other diseases from the plasma of recovered 
patients. In addition, antibodies in plasma are usually at a lower 
concentration, which may not be sufficient for therapy. The 
company of Regeneron in the USA is about to present two 
antibodies that can synthetically be produced for the treatment 
of COVID-19, and clinical studies would be started later. These 
antibodies would be useful for prophylaxis and treatment in 
particularly high-risk groups [35]. The US-FDA has approved 
the use of convalescent plasma for patients with severe or 
immediately life-threatening COVID-19. Efficacy and safety of 
convalescent plasma for the treatment of COVID-19 have not 
been established yet [49]. 
 
Other agents  
Inhaled nitric oxide (iNO) has been known as an efficient and 
selective pulmonary vasodilator. It also has an antimicrobial 
effect. Because of these factors iNO is used to treat respiratory 
diseases such as pulmonary hypertension and ARDS. It has a 
relatively good safety profile and maybe a promising candidate 
in treating severe COVID-19 patients, as it alleviates lung 
damage [12]. The Surviving Sepsis Campaign has 
recommended a trial of the inhaled pulmonary vasodilator in 
COVID-19 patients with severe ARDS and hypoxemia who 
have mechanically ventilated despite optimized ventilation and 
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other recovery strategies. Inhaled epoprostenol, which is 
naturally occurring prostaglandin and inhaled nitric oxide, are 
two pulmonary vasodilators that have been investigated 
commonly [26]. Based on a randomized controlled trial with an 
experience with inhaled epoprostenol, it has been observed that 
the mean pulmonary artery pressure decreased, and oxygenation 
improved in patients with ARDS. However, additional data 
related to inhaled epoprostenol is needed in the treatment of 
ARDS [21,26].   
     Vitamin C is a potent antioxidant agent since it can 
neutralize free radicals, prevent, and reverse cellular damage. 
Vitamin C, which is known to be effective against influenza, is 
an effective antiviral agent. Some hospitals have been reported 
administering high doses of vitamin C as supportive treatment 
to infected patients. In China, it has been observed that the 
oxygenation index of 50 moderate-severe patients who received 
high doses of vitamin C was improved, and all patients 
eventually recovered and discharged. Doses were administered 
with IV infusion over 8–10 hours among 2 and 10 g per day. 
The NIH panel stated that 1.5 mg/kg vitamin C is safe and does 
not cause side effects [26].  
     Colchicine is an agent with anti-inflammatory and 
antifibrotic properties, and it is often used for the treatment of 
gout. Colchicine has been shown to reduce inflammation in 
cardiac myocytes in some COVID-19 patients with myopathy. 
There are several ongoing studies to investigate the effect of 
colchicine in a cytokine storm [26]. 
 
Concomitant use of certain drugs in patients with 
COVID-19  
Angiotensin-converting enzyme inhibitors and angiotensin 
II receptor blockers (ARBs)  
SARS-CoV-2 has some similarities with SARS-CoV and 
MERS-CoV in terms of their mechanisms. According to the 
findings from several studies with the SARS-CoV, it has been 
considered that angiotensin-converting enzyme 2 (ACE2) acts 
as a co-transporter for the virus to enter the lungs [50]. Similar 
to the SARS-CoV, SARS-CoV-2 also enter the lungs after the 
binding to ACE2 [51]. ACE2 is an enzyme and a receptor on 
cell surfaces for SARS-CoV and SARS-CoV-2 and is expressed 
in the lung, heart, kidney, and testis [52]. It is a homologue of 
ACE1, an important therapeutical target in cardiovascular 
diseases (CVD) [51]. ACE1 converts the angiotensin I to 
angiotensin II. Angiotensin II causes an increase in blood 
pressure. The ACEI inhibit angiotensin I to angiotensin II 
conversion and widely used in CVD. The effects of ACE2 is 
not as clear as ACE1, and there is no specific treatment 
involving ACE2 [50,51]. However, it has been known that 
ACE2 degrade the angiotensin II to angiotensin (1-7), so it 
affects the renin-angiotensin system significantly by 
antagonizing the role of angiotensin II [53]. 
     This association between the ACE2 and SARS-CoV-2 has 
questioned the use of ACE inhibitors and ARBs since these 
drugs could lead to increased expression of ACE2. The 
increased expression of ACE2 may ease the viral entry to cells 
and increase the risk of becoming infected [54]. American Heart 
Association (AHA), American College of Cardiology (ACC), 
Heart Failure Society America (HFSA), and European Society 
of Cardiology (ESC) recommend continuing treatment with 
ACE inhibitors or ARBs. Furthermore, these agents have an 
important role in patients with hypertension and those with 
heart failure and proteinuria. Thus, particularly in high-risk 
patients, discontinuation of treatment could lead to more severe 
and adverse health outcomes such as uncontrolled hypertension, 
renal function impairment, and cardiac decompensation (12,21). 
It has been considered that the use of ACE inhibitors and ARBs 
in COVID-19 might be beneficial due to its potential anti-
inflammatory effects. Induced ACE2 activity causes an increase 
in conversion of angiotensin II to angiotensin (1-7), and this 
final peptide can produce anti-inflammatory activity. However, 
it is not sure whether the anti-inflammatory activity is harmful 
or beneficial in SARS-CoV-2 infection [55].  
     As a consequence, there is insufficient data about the effects 
of ACE inhibitors and ARBs in patients with COVID-19. It is 
recommended that patients treated with ACE inhibitors or 
ARBs for cardiovascular disease should continue these 
medications [27]. 
 
Non-steroid anti-inflammatory drugs (NSAIDs)  
In France, four patients with COVID-19 and no underlying 
health problems have developed serious complications after 
using NSAIDs. Therefore, in mid-March 2020, it was 
recommended that ibuprofen should not be used in patients with 
COVID-19 for symptomatic relief [56,57]. Additionally, it has 
been proposed that ibuprofen can increase the expression of 
ACE2 [58]. Currently, there is no sufficient evidence in order to 
recommend against the use of ibuprofen and other NSAIDs in 
patients with COVID-19, and patients may need NSAIDs for 
symptom relief if paracetamol is inadequate. Nevertheless, 
regular use of NSAIDs is not recommended as a first-line drug 
option, and paracetamol is the preferred antipyretic agent in 
patients with COVID-19 [21,67]. 
 
Corticosteroids  
Corticosteroids are generally not recommended in patients with 
COVID-19 unless indicated for another condition such as 
exacerbation of asthma or COPD. Patients received oral 
corticosteroid therapy before the SARS-CoV-2 infection should 
continue their treatment. Similarly, inhaled corticosteroids used 
daily to treat asthma, and COPD should not be discontinued in 
patients with COVID-19 [21,27]. 
 
Anticoagulants  
According to the preliminary reports, hemostatic abnormalities 
occur in patients with COVID-19 [60]. The endothelium has an 
essential role in haemostasis regulation, but this regulation is 
generally disrupted during viral infections [61]. It is one of the 
reasons for hemostatic abnormalities in patients with COVID-
19. Mild thrombocytopenia and increased D-dimer levels 
associated with worse clinical outcomes are instances of 
hemostatic abnormalities in COVID-19 patients [60].  
     The International Society for Thrombosis and Haemostasis 
(ISTH) and American Society of Hematology (ASH) 
recommend prophylactic dose low molecular weight heparin 
(LMWH) to all hospitalized COVID-19 patients, including non-
critical ill patients. Unless they have contraindications for 
LMWH such as active bleeding and platelet count < 25 x 109/L 
[62]. Also, WHO interim guidance statement recommends the 
use of once-daily LMWH or twice daily subcutaneous 
unfractionated heparin (UFH) as thromboprophylaxis. Some 
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clinicians use a higher dose or therapeutic dose parenteral 
anticoagulant in COVID-19 patients. However, additional 
studies are necessary to evaluate this situation. LMWHs can be 
more advantageous over UFH due to the once-daily dosing 
regimen [60]. LMWH or UFH is generally preferred in 
hospitalized patients' thromboprophylaxis because they have 
shorter half-lives, can be administered intravenously or 
subcutaneously, and have fewer drug-drug interactions in 
comparison to oral anticoagulants. Patients who receive 
anticoagulant or antiplatelet agents for underlying conditions 
should continue their treatment [27]. 
 
Statins  
Statins have the function of reducing endothelial dysfunction; in 
this way, they affect ACE2 [27]. Furthermore, these lipid-
lowering agents have anti-inflammatory and 
immunomodulatory effects. Therefore, with statins, lung injury 
caused by the body's immune response may be controlled [63]. 
Patients with COVID-19 who are on use statins for a CVD 
should continue not to disrupt statin [27]. Discontinuation of 
statin therapy may be recommended in patients who may 
develop severe rhabdomyolysis. Drug interactions may occur 
with concomitant use of statins and medications used for the 
treatment of COVID-19 [21]. 
 
Comorbidities in COVID-19 – diabetes mellitus and 
hypertension  
According to various studies, diabetes and hypertension are 
highly prevalent comorbidities among patients with COVID-19 
[50]. Also, it has been reported that SARS-CoV-2 may cause 
injury to other organs such as the heart, liver, and kidneys in 
addition to pneumonia. Thus, especially in older patients with 
underlying comorbidities paying full attention in the treatment 
of original comorbidity is necessary [64,65]. 
     Various mechanisms may explain the susceptibility of 
patients with diabetes in SARS-CoV-2 infection. Decreased 
pulmonary function, including a reduction in forced vital 
capacity and forced expiratory volume, decreased viral 
clearance and T cell function, and aggravated inflammation are 
instances of these mechanisms that generally occur due to 
hyperglycemia [65–67]. Therefore, in patients with diabetes 
controlling blood glucose is crucial, and these patients should 
be monitored closely.  
     Hypertension is another comorbidity and common disease, 
particularly in older. Patients with hypertension are also in high-
risk groups for COVID-19. Moreover, there is an important 
issue with the medications of patients with hypertension. ACE 
inhibitors and ARBs are widely used drugs for the treatment of 
hypertension. However, there are conflicting considerations 
available about the use of them in patients with COVID-19. 
Thus, patients with hypertension can be confused and unwilling 
about the continuation of treatment. Health care providers 
should ensure that these patients continue their treatment 
because discontinuation of treatment could lead to uncontrolled 
hypertension, which is more dangerous in COVID-19 [12].  
      Patients with hypertension or/and diabetes should be aware 
that uncontrolled blood pressure or blood glucose levels may 
increase the severity of COVID-19. Thus, they should receive 
their medications properly, maintain a healthy lifestyle, and 
follow health authorities' recommendations about prevention 
and control [68,69]. 
Healthcare professionals have a great responsibility for patient 
education. Especially clinical pharmacists who use all their 
pharmaceutical knowledge for the benefit of patients can 
improve health status by ensuring proper medication use [92]. 
 
Managing symptoms of COVID-19  
There are various symptoms of COVID-19, such as fever, 
cough, difficulty breathing. The presence and severity of 
symptoms vary from one patient to another. In addition to 
antiviral and investigational drugs mentioned above in detail, 
there are also drugs and recommendations for managing 
COVID-19 symptoms. In managing the symptoms, several 
factors should be considered, such as the patient's underlying 
conditions and other drugs used by the patient. There are 
several methods listed below that can be applied to manage 
symptoms: 
 
• Firstly, simple non-medication remedies such as honey can 
relieve cough, but it is not safe for children under the age of 1. 
The short term use of codeine linctus or tablets and morphine 
sulfate oral solution may be considered if coughing is 
distressing in patients with COVID-19. Patients should be 
informed about the constipation effect of codeine and morphine. 
 
• Generally, paracetamol is the recommended agent for the 
management of fever. There is no recommendation against the 
use of NSAIDs, but paracetamol is generally preferred 
antipyretic in patients with COVID-19. Also, patients should 
drink enough water to avoid dehydration. 
 
• Breathing and relaxation techniques, ventilating the room 
frequently can help manage difficulty breathing in patients with 
COVID-19 [70]. 
 
Drug-vaccine studies for COVID-19 
An overview of drug studies  
Repurpose drugs can provide new treatment options faster than 
the discovery of new drugs, as the safety profiles of existing 
drugs already exist. For this purpose, bioinformatics' use to 
analyze the interactions of drugs with the proteins of the target 
organism is a method for effectively selecting drugs against 
SARS-CoV 2 [71]. Until now, researchers have suggested more 
than 30 drugs (remdesevir, favipiravir, indinavir, raltegravir, 
darunavir/cobicistat, saquinavir, etc.) with possible effects 
against COVID-19 [37]. General corticosteroids and established 
antiviral drugs, including neuraminidase inhibitors (oseltamivir, 
zanamivir, peramivir, etc.), acyclovir, ganciclovir, and ribavirin 
have found unacceptable for use in general clinical practice, and 
these are not recommended for the prevention and treatment of 
COVID-19 [72].  
     There is currently a large global trial known as Solidarity, 
supported by the World Health Organization (WHO). These 
trials include four repurposed drugs as potential therapeutic 
agents: chloroquine and hydroxychloroquine, remdesivir, 
lopinavir, and ritonavir combination with or without interferon 
[12,73]. As of April 21, 2020, more than 100 countries are 
working together to find effective therapeutics in the shortest 
possible time. Enrolling patients in one randomized trial will 
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facilitate the rapid comparison of unproven treatments 
worldwide, and while randomized clinical trials usually take 
years, time spent will decrease by percent 80. On 4 July 2020, 
WHO accepted the recommendation from the Solidarity Trial's 
International Steering Committee to discontinue the 
hydroxychloroquine and lopinavir/ritonavir arms of the trials 
[73]. A record of international clinical trials can be found on the 
WHO website and at ClinicalTrials.gov. At present, the 
evidence needed for the efficacy and safety of treatments 
against COVID- 19 will be provided by randomized controlled 
trials. Thus, we will determine whether the benefits of most 
treatments outweigh the harms [25]. While searching for the 
"COVID-19" term on the ''Clinicaltrials.com'' website, there are 
a total of 3176 studies; 1649 of them are recruiting. Among 
these, 913 studies are interventional (clinical trials), and among 
these are 378, 205, 46 studies in phase 2, phase 3, phase 4, 
respectively [74]. Drugs that are included in clinical studies 
mainly are antiviral drugs, immunotherapy drugs (such as 
Interferon, Immunoglobulin, etc.), antimalarial drugs (such as 
chloroquine, hydroxychloroquine, chloroquine phosphate), 
glucocorticoids, traditional Chinese medicine interventions, and 
others (such as vitamin C, vitamin D, polymyositis injection, 
zinc sulfate, acetylcysteine, etc.) [19].  
     Besides, the FDA has issued guidance for investigation of 
convalescent plasma in the United States for COVID-19. It is 
essential to establish protocols for collecting, preparing, and 
applying apheresis-collected convalescent plasma in response to 
the current pandemic [12]. Clinical trials are ongoing in China 
to evaluate the use of convalescent serum for treatment [75]. 
 
Vaccine Development for COVID-19  
Based on the small SARS-CoV-1 vaccine studies in phase 1, 
these studies' results with an inactivated virus vaccine and a 
spike-based DNA vaccine are promising as they induced 
neutralizing antibody titers and were safe. It is thought that 
cross-protection can be provided against SARS-CoV-2 with 
some neutralizing monoclonal antibodies isolated against 
SARS-CoV-1, such as CR3022. Vaccines developed against 
MERS-CoV targeting the MERS-CoV S protein are in 
preclinical and clinical development. However, MERS-CoV 
vaccines are not thought to induce potent cross-neutralizing 
antibodies due to the phylogenetic distance between the two 
viruses [75]. For the development of CoV vaccines, most of 
these targets are spike (S) glycoprotein that elicited 
neutralizing-antibodies and T-cell responses [76].  
     The effect of vaccines' protection may depend on various 
factors such as the selected vaccination platform, antigens, 
animal models, and ways of vaccination. Different ways of 
vaccination could also help to develop effective vaccines for 
coronaviruses [77]. Candidate vaccines are in development, but 
it may take at least 12 to 18 months [78]. Thirty-three vaccine 
candidates are currently approved for human testing through 
clinical trials, including mRNA and DNA platform vaccines, 
adenovirus vector vaccines, and inactivated virus vaccines [79]. 
Nine of them are in the Phase 3 clinical trial (Table 3). 
Generally, DNA-based, and protein-based vaccines have been 
the main approaches for developing stable and effective 
vaccines with less innate immunogenicity [78]. In addition, 
mRNA-based vaccines are safer, efficient, and easier to 
manufacture, and unlike traditional vaccines made from an 
inactivated pathogen or small subunits of living pathogen, 
synthesis of this vaccine does not require viruses [78,80]. 
Recently, various DNA vaccine platforms have been developed 
to promote vaccines' efficacy by using electroporation to deliver 
plasmids encoding antigens and diverse immune responses and 
adding adjuvants to promote immune responses. In this context, 
Inovio Pharmaceuticals and International Vaccine Institute is 
developing a DNA vaccine (INO-4800) against COVID-19, and 
the vaccine is in clinical phase I/II stage [79,81] ChAdOx1-S 
COVID-19 vaccine, which entered the phase 3 clinical study 
developed by the University of Oxford in partnership with 
AstraZeneca, consists of the S protein sequence of SARS-CoV-
2 and a non-replicating adenovirus vector. Adenovirus-based 
vectors cover respiratory, and Gi epithelium, the two major sites 
in which SARS-CoV-2's ACE-2 receptor is expressed, and 
these are relatively safe in children and individuals with 
underlying disease due to its non-replication in the host [80]. 
On March 16, 2020, phase 1 clinical trial of novel lipid 
nanoparticle (LNP)-encapsulated mRNA-based vaccine has 
been started jointly by Moderna and the Vaccine Research 
Center at the National Institutes of Health [78], and this vaccine 
is currently in phase 3 clinical trial. The immunogenicity and 
efficacy of the inactivated SARS-CoV vaccines were detected 
in experimental animals [82].  
     Currently, there are six candidate inactive vaccines in the 
clinical evaluation stage [79]. Preclinical trials have been 
started for some of the SARS-CoV-2 vaccine candidates [75]. 
143 candidate vaccines are in the preclinical phase [79]. 
Additional vaccine approaches in the preclinical stage include 
DNA vaccines, live attenuated vaccines, inactivated virus 
vaccines, recombinant-protein based vaccines, and viral-vector-
based vaccines. It is difficult to predict which of these platforms 
will be more successful or faster because all of them have 
advantages and disadvantages [75]. 
 
Conclusion  
COVID-19 had a massive impact on every aspect of life. 
Healthcare workers and researchers are working hard either to 
treat or find a permanent solution to this pandemic. With 
preventive measures, the number of new cases will be kept 
reduced. There are several medicine options frequently used for 
COVID-19. However, these drugs are not absolute and have 
many side effects. Many of these drugs may not be familiar to 
the physician and require a clinical pharmacist's professional 
support. A healthcare professional team containing physicians, 
pharmacists, nurses, physiotherapists, etc. needs to collaborate. 
Interdisciplinary plans should be created to obtain the most 
relevant results. COVID-19 is the first pandemic of the 21st 
century and tested the global health system's readiness under a 
pandemic. It revealed some of the strengths of the health system 
while showing us the parts that required improvement. After the 
COVID-19 pandemic, we will have the opportunity to analyze 
these weaknesses and take the necessary measures to ensure the 
health system's better performance under future pandemics. 
Future preparedness is another important issue to prevent 
catastrophic outcomes of a pandemic. Emergency protocols, 
teams, guidelines, and budget should be ready for future 
pandemics. Besides healthcare workers, these teams should 
contain different occupational professionals.  
                                                     Sosyal D, et al. Journal of Ideas in Health (2020); 3(4):228-242                                                               236  
 
 
Table 1 Properties of select proposed drugs for treatment of COVID-19 
Agent/ Class Target/Clinical Use FDA-Approved 
Indications 










and glycosylation of host 
receptors.  
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immunomodulatory 
effects with autophagy, 
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inhibition of cytokine 
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• Co-administration with 
drugs highly dependent on 
CYP450 3A. 
• Co-administration with 
potent CYP450 3A 
inducers.  
• Its effectiveness in the 
use of COVID-19 
treatment with other 






• S protein/ACE2, 
membrane fusion 
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to umifenovir  
•Included in some 
guidelines for the 
treatment of COVID-19.  
•There are limited data on 






• RNA polymerase 
inhibitor 




•Exclusion criteria based 
on specific protocols 
• It is the most promising 
direct-acting antiviral 
currently being researched 
for COVID-19. 
• Efficacy and safety of 
remdesivir for treatment 
of COVID-19 not 
established. 
• NIH indicates 
insufficient clinical data 
for the use of remdesivir 
 
[21,86] 
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should be taken to prevent 
• Efficacy and safety of 
favipiravir for 
treatment of COVID-19 
not established. 
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• In China, tocilizumab 
can be used for treating 
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COVID-19 patients with 
extensive lung lesions and 
high IL-6. 
• NIH reports insufficient 




Table 2 Practical Information on Potential Therapeutic Agents for Treatment of COVID-19 
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COVID-19: Coronavirus Disease-2019; SARS-CoV-2: Severe 
Acute Respiratory Syndrome Coronavirus 2; MERS-CoV: 
Middle East Respiratory Syndrome Coronavirus; ACE: 
Angiotensin Converting Enzyme; NIH: National Institutes of 
Health; WHO: World Health Organization; FDA: Food and 
Drug Administration; CDC: Centers for Disease Control and 
Prevention; IDSA: Infectious Diseases Society of America; 
ARDS: Acute Respiratory Distress Syndrome;  NSAIDs: Non-
steroidal Anti-inflammatory Drugs; LMWH: Low Molecular 
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